Free Trial

Hillstream BioPharma (HILS) Competitors

Hillstream BioPharma logo
$1.53 -0.13 (-7.83%)
As of 07/24/2025

HILS vs. VIRI, WHWK, PYRGF, AADI, ATNM, NBRV, OSTX, ELYM, NNVC, and EGRX

Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), Aadi Bioscience (AADI), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), OS Therapies (OSTX), Eliem Therapeutics (ELYM), NanoViricides (NNVC), and Eagle Pharmaceuticals (EGRX).

Hillstream BioPharma vs. Its Competitors

Hillstream BioPharma (NASDAQ:HILS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

13.4% of Hillstream BioPharma shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hillstream BioPharma has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Virios Therapeutics has a consensus target price of $5.00, indicating a potential upside of 5.71%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Virios Therapeutics is more favorable than Hillstream BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hillstream BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Virios Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Virios Therapeutics' return on equity of -130.33% beat Hillstream BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Hillstream BioPharmaN/A -188.44% -149.61%
Virios Therapeutics N/A -130.33%-115.00%

In the previous week, Hillstream BioPharma's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company Overall Sentiment
Hillstream BioPharma Neutral
Virios Therapeutics Neutral

Virios Therapeutics is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hillstream BioPharmaN/AN/A-$8.47M-$0.72-2.13
Virios TherapeuticsN/AN/A-$5.30M-$0.27-17.52

Summary

Virios Therapeutics beats Hillstream BioPharma on 6 of the 10 factors compared between the two stocks.

Get Hillstream BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HILS vs. The Competition

MetricHillstream BioPharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$26.93M$776.90M$5.70B$9.50B
Dividend YieldN/A4.84%4.69%4.01%
P/E Ratio-2.131.4028.1020.06
Price / SalesN/A25.35428.7189.10
Price / CashN/A19.5636.2258.56
Price / Book3.196.798.665.87
Net Income-$8.47M-$4.32M$3.25B$258.55M
7 Day Performance-9.47%1.15%4.22%3.73%
1 Month Performance-7.83%3.76%10.51%11.75%
1 Year Performance-50.32%9.52%34.40%18.02%

Hillstream BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HILS
Hillstream BioPharma
N/A$1.53
-7.8%
N/A-51.1%$26.93MN/A-2.131Gap Down
VIRI
Virios Therapeutics
N/A$5.08
+6.7%
$5.00
-1.6%
+1,940.6%$97.83MN/A-18.815
WHWK
Whitehawk Therapeutics
N/A$1.96
+1.0%
N/AN/A$92.34M$25.98M12.2540
PYRGF
PyroGenesis Canada
N/A$0.32
+0.5%
N/A-52.3%$60.45M$9.14M-5.3890
AADI
Aadi Bioscience
0.3779 of 5 stars
$2.05
+7.3%
$1.67
-18.7%
+20.5%$50.63M$25.07M-0.9040
ATNM
Actinium Pharmaceuticals
2.4484 of 5 stars
$1.56
+4.4%
$4.00
+157.2%
N/A$48.51MN/A-1.1230Positive News
Gap Up
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
OSTX
OS Therapies
2.0558 of 5 stars
$1.58
-0.3%
$18.00
+1,042.9%
N/A$44.25MN/A-1.83N/A
ELYM
Eliem Therapeutics
N/A$1.42
+3.6%
N/A-83.4%$42.25MN/A-2.689Gap Down
NNVC
NanoViricides
0.3518 of 5 stars
$1.66
+13.4%
N/A-24.0%$26.60MN/A-2.3020
EGRX
Eagle Pharmaceuticals
2.4345 of 5 stars
$3.74
+5.4%
N/A-35.7%$23.38M$257.55M0.00100Gap Down

Related Companies and Tools


This page (NASDAQ:HILS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners